

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 May 2026

The effect of Curcumin on Oxidant , Antioxidant factors ,Liver ,Kidney tests serum , Clinical signs and symptoms of MultipleSclerosis patients

Protocol summary

Study aim

The effect of curcumin on oxidant , antioxidant factors , liver ,kidney tests serum , clinical signs and symptoms of multiple sclerosis patients

Design

Clinical practice with control group, parallel, double-blind, randomized, phase 3 over 96 patients, blocked randomization method

Settings and conduct

The clinics of Arak University of Medical Sciences will be double-blind and patients will be divided into two groups of cases and Dronoma as blocked randomization with 4 and 6 block sizes. The doctor's secretary (who has no knowledge of the type of capsules and the group of patients in which they are placed) will be given. Thus, the researcher, the specialist, the patient will be blinded.

Participants/Inclusion and exclusion criteria

Ms have RRMS, age 18 to 50, and EDSS (less than 4). Patients who have been diagnosed with MS for at least a year have no gastrointestinal problems. Don't take zinc supplements or selenium supplements. Anthocyanin-like corticosteroids, such as vitamin EA-D, haven't been used for at least the past two weeks. Don't be pregnant. Don't be breastfeeding women

Intervention groups

Razak 270 mg Corkomine Capsule, Stanoma Pharma Capsule Capsule

Main outcome variables

Total Oxidative Capacity, Oxygenated Water, Malondialdehyde, Revitalizing Glutathione, Dysmotaz Super Oxide, Alanine Amino Transfer, Aspartate Amino Transfer, Nitrogen Urea Blood, Blood Creatinine, Fatigue, gait disorders and severe disability

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200614047766N1**

Registration date: **2020-06-30, 1399/04/10**

Registration timing: **prospective**

Last update: **2020-06-30, 1399/04/10**

Update count: **0**

Registration date

2020-06-30, 1399/04/10

Registrant information

Name

Zahra Godarzi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 86 3276 3822

Email address

kiyangolmohamadi@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-09-21, 1399/06/31

Expected recruitment end date

2021-02-18, 1399/11/30

Actual recruitment start date

2020-09-21, 1399/06/31

Actual recruitment end date

2021-02-18, 1399/11/30

Trial completion date

2021-06-21, 1400/03/31

Scientific title

The effect of Curcumin on Oxidant , Antioxidant factors ,Liver ,Kidney tests serum , Clinical signs and symptoms of MultipleSclerosis patients

Public title

Investigation of the effect of curcumin in Multiple Sclerosis

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:
The study subjects must have RRMS type Ms disease They are 18 to 50 years old and EDSS (disease incapacity severity) must be less than 4 Patients who have been diagnosed with MS for at least one year Patients who do not have a specific digestive problem (gastric and duodenal ulcers, irritable bowel syndrome, indigestion) Not sensitive to curcumin They do not receive zinc or selenium supplements Antioxidant corticosteroids, such as vitamin E-A-D, have not been used for at least the past two weeks. They are not pregnant Don't be a breastfeeding woman They do not have special liver or kidney problems

Exclusion criteria:
Lack of willingness of the patient to continue cooperation patients with mental disorders

Age
From **18 years** old to **50 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size
Target sample size: **96**
Actual sample size reached: **96**

Randomization (investigator's opinion)
Randomized

Randomization description
Patients with divided randomization with block sizes of 4 and 6 blocks will be divided into two groups of cases (MS patients who will receive curcumin in 48 people) and Dardonema (MS patients who will receive placebo in 48 people). In this way, we paste 96 randomly selected codes on 96 cans of capsules that are similar in color, shape and size, and after pouring the curcumin capsule and placebo capsule according to the codes in the cans, we put all the cans. Pour into a bag.

Blinding (investigator's opinion)
Double blinded

Blinding description
According to the codes we have, Razak's 370 mg curcumin capsules will initially be given twice daily to the CASE group and the placebo-containing placebo capsule to the placebo group by the doctor's secretary (who has no knowledge of the type of capsules or what group of patients are in which). In this way, the doctor, the researcher and the patient have no knowledge of the groups

Placebo

Not used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ethics Committee of Arak University of Medical Sciences

Street address
Deputy of Research and Technology, Payambar Azam University Complex, Basij Square, Sardasht St

City
Arak

Province
Markazi

Postal code
3848176341

Approval date
2020-06-08, 1399/03/19

Ethics committee reference number
IR.ARAKMU.REC1399.068

Health conditions studied

1

Description of health condition studied
Multiple Sclerosis

ICD-10 code
G35

ICD-10 code description
Demyelinating diseases of the central nervous system

Primary outcomes

1

Description
Total oxidative status

Timepoint
Measurement of total oxidative status at the beginning of the study (before the start of the intervention) and 3 months after the start of use of curcumin capsules

Method of measurement
Total Oxidative Status Measurement Kit

2

Description
Malone Dialdehyde

Timepoint
Measurement of malondialdehyde at the beginning of the study (before the intervention) and 3 months after the

start of use of curcumin capsules

Method of measurement

Malon dialdehyde Measurement Kit

3

Description

آب اكسيژنه

Timepoint

Measurement of oxygenated water at the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules

Method of measurement

Oxygenated water measurement kit

4

Description

Super Oxide Dismutase

Timepoint

Measurement of dismutase superoxide at the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules

Method of measurement

Dysmotase Super Oxide Measurement Kit

5

Description

Glutathione Revival

Timepoint

Measurement of glutathione reductase at the beginning of the study (before the start of the intervention) and 3 months after the start of the use of curcumin capsules

Method of measurement

Glutathione Revitalization Measurement Kit

6

Description

Aspartate amino transferase

Timepoint

At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin

Method of measurement

Aspartate aminotransferase assay kit

7

Description

Alanin amino transferase

Timepoint

The beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin

Method of measurement

Alanine Amino Transfer Measurement Kit

8

Description

Blood creatinine

Timepoint

At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin

Method of measurement

Creatine measuring kit

9

Description

Nitrogen in the blood urea

Timepoint

At the beginning of the study and 3 months after taking curcumin

Method of measurement

Blood urea nitrogen measurement kit

Secondary outcomes

1

Description

Expanded Disability Status Scale

Timepoint

At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules

Method of measurement

questionnaire

2

Description

Fatigue Severity Scale

Timepoint

At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules

Method of measurement

questionnaire

3

Description

Gait disorder

Timepoint

At the beginning of the study (before the start of the intervention) and 3 months after the start of use of curcumin capsules

Method of measurement

25 foot test

Intervention groups

1

Description

Intervention group: Intervention group: MS patients who take Corkomine oral capsule for 3 months at a dose of 370 mg, take one a day at the beginning of the study and then take it twice a day. It has high antioxidant properties.

Category

Treatment - Drugs

2**Description**

Control group: MS patients who receive placebo for 3 months

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Kosar Clinic

Full name of responsible person

Zahra Goodarzi

Street address

No. 3634, Kosar specialized clinic, Seyedha mosque, Imam khomeini st, Arak

City

Arak

Province

Markazi

Postal code

3814113634

Phone

+98 86 3223 3823

Email

it.kousar@arakmu.ac.ir

2**Recruitment center****Name of recruitment center**

Imam Reza Clinic

Full name of responsible person

Zahra Goodarzi

Street address

No.9589, Shahid Shiroudi St, Arak

City

Arak

Province

Markazi

Postal code

3813899589

Phone

+98 86 3240 2002

Email

farahaniheidar@yahoo.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Arak University of Medical Sciences

Full name of responsible person

Alireza Kamali

Street address

No.6341, Deputy of Research and Technology, University Complex of the Great Prophet, University of Medical Sciences, Basij Square, Sardasht St. Arak

City

Arak

Province

Markazi

Postal code

3848176341

Phone

+98 86 3417 3639

Email

research@arakmu.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Arak University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Arak University of Medical Sciences

Full name of responsible person

Zahra Goodarzi

Position

University Student

Latest degree

Bachelor

Other areas of specialty/work

Biochemistry

Street address

No. 9881, 30 Shams Alley, Football Street

City

Arak

Province

Markazi

Postal code

3815899881

Phone

+98 86 3276 3858

Email

kiyangolmohamadi@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Alireza Rezaei Ashtiani

Position

specialist

Latest degree

Specialist

Other areas of specialty/work

Neurology

Street address

No.3345, Mir Ahmad Doctors Building, Adalat Alley,
Shahid Beheshti St, Arak

City

Arak

Province

Markazi

Postal code

۳۸۱۹۶۹۳۳۴۰

Phone

+98 86 3223 9388

Email

farahaniheidar@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Haidar Farahani

Position

Associate Professor

Latest degree

Ph.D.

Other areas of specialty/work

Biochemistry

Street address

Biochemistry section, Medical School, University
Complex of the Great Prophet, Basij Square, Sardasht
St, Arak

City

Arak

Province

Markazi

Postal code

3848176341

Phone

+98 86 3417 3520

Email

farahaniheidar@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to
make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to
make this available

Statistical Analysis Plan

Not applicable

Informed Consent Form

Undecided - It is not yet known if there will be a plan to
make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to
make this available

Analytic Code

Not applicable

Data Dictionary

Undecided - It is not yet known if there will be a plan to
make this available